# Trialjectory

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trialjectory

- Industry: Healthcare IT
- Headquarters: Stamford, US
- Website: www.trialjectory.com
- Total disclosed funding: $28M
- Latest round: Series A (Jan 31, 2022)
- Investors on record: 6

## About

Trialjectory Inc. is a digital health company that leverages AI to optimize cancer treatment access, offering personalized decision support for patients navigating their treatment options.Founded in 2017 and headquartered in Stamford, US, Trialjectory Inc. specializes in providing a platform that aids cancer patients in finding suitable treatments. The company has successfully raised funding in three rounds, with the latest being a Series A round of USD 20.00 mn in January 2022, led by Insight Partners and including contributions from Contour Venture Partners and others. The founders include Avital Gaziel, Noam Geva, and Tzvia Bader, with Tzvia Bader currently serving as CEO.Trialjectory's platform offers an AI-driven decision support tool designed to provide patients with personalized cancer treatment options based on their specific diagnoses. Users select their cancer type and complete a questionnaire, receiving tailored treatment recommendations that include available therapies and clinical trials. The service caters to patients, healthcare providers, and pharmaceutical companies, demonstrating a comprehensive approach to cancer care, currently operational in the US and Canada.Trialjectory generates revenue primarily through partnerships with healthcare providers and pharmaceutical firms, operating on a B2B model. Healthcare institutions integrate Trialjectory's technology into their services, allowing for access to personalized treatment recommendations. Revenue generation includes subscription fees for providers and service fees associated with patient treatment matching, reflecting the value of their AI-driven services.In January 2022, Trialjectory raised USD 20.00 mn in Series A funding, aimed at redefining cancer care through personalized treatment decision support. The company plans to utilize this funding to expand its market presence, with a focus on delivering patient-centered experiences for pharmaceutical partners. Trialjectory is targeting new regions for expansion, with plans to enhance its platform offerings and broaden its geographic reach in the coming years.

## Funding rounds

- Series A, Jan 31, 2022, $20M — RHO, Insight Partners, Contour Venture Partners, JAL Ventures, TIA Ventures
- Series A, Feb 10, 2021, $5M — RHO, Contour Venture Partners, Connecticut Innovations, TIA Ventures
- Seed, Dec 17, 2019, $2.7M — Contour Venture Partners

## Investors

- Contour Venture Partners (https://capitalatlas.ai/funds/contour-venture-partners) — Seed, Series A
- RHO (https://capitalatlas.ai/funds/rho) — Series A
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A
- TIA Ventures (https://capitalatlas.ai/funds/tia-ventures) — Series A
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series A
- JAL Ventures (https://capitalatlas.ai/funds/jal-ventures) — Series A